

## Senior Management

**Dr. John Kulp, CEO:** John has a broad background including senior management positions with responsibility for product development, research, operations, business development, and strategic planning, related to advanced information technologies and applications. He has a 10-year background in BioLeap's core technologies, achieving several innovations in fragment-protein simulations. He founded the large-scale biophysical simulation team at Sarnoff Corp. where he was Vice President, and has played a leading role in a number of successful business launches. John's PhD is in Electrical Science (statistical physics) from MIT.

**Dr. Ian S. Cloudsdale, VP of Chemistry:** Ian has a broad background including senior management positions within the pharmaceutical, agrochemical and biotechnology industries. He has over 20 years of experience with Syngenta, Novartis and Sandoz. Ian's PhD is from Cambridge University in Synthetic Chemistry and he has over two years experience with computational fragment-based drug design.

**Dr. Clive Hammant, VP Licensing:** Clive's 34 year career in the pharmaceutical industry commenced with the Wellcome Foundation in Central Africa and Brazil and continued at Pfizer, during which he covered licensing deals including inhaled insulin (Nektar), recombinant insulin sourcing (Hoechst), trovafloxacin intermediates (Toyama) and fesoterodine (UCB.) Clive received his MA and Vet MB degrees from Cambridge University.

**Gerald H. Evans, EVP:** Gerry started his business career at the corporate headquarters of Mobil Corporation. He has a broad base of direct management and consulting experience with an emphasis on building new companies. Gerry is a cofounder of and the former Chairman of the New Jersey Entrepreneurial Network. His degree is in business from the Pennsylvania State University.

**Dr. David L. Pompliano, Adviser:** David has eighteen years of leadership experience in the pharmaceutical industry with a focus on driving strategic change in research and development. Most recently he served as Vice President, Worldwide Basic Head, Vaccines and Infectious Diseases Franchise for Merck Research Laboratories. Prior to Merck, David was Vice President, Head of Biology, Infectious Diseases Center for Excellence in Drug Discovery at GlaxoSmithKline. As a drug hunter, David has contributed to the discovery or development of two marketed drugs (Tykerb and Altabax) and four drugs that have reached clinical proof of concept (pazopanib, ronacaleret, Rezonic, and Promacta). He is an internationally recognized scientist and innovator who has published >50 research papers, has given >25 invited lectures internationally and holds three patents for novel methods in drug discovery.

**Dr. Leslie J. Browne, Adviser:** Les has over twenty-five years of leadership experience in the pharmaceutical industry. Most recently he served as President, CEO and Director of Pharmacopeia. Prior to joining Pharmacopeia, Dr. Browne was the Chief Operating Officer at Iconix Pharmaceuticals, Inc., where he led research, development and informatics operations. Prior to Iconix Dr. Browne held key positions at Berlex/Schering AG, including Corporate Vice President, Berlex Laboratories, Inc. and President of Schering Berlin Venture Corporation.

**Dr. Raymond Salemme, Adviser:** Ray brings more than 30 years of broad biotechnology and entrepreneurial expertise to BioLeap. Dr. Salemme is currently the CEO of Redpoint Bio. Previously Dr. Salemme was the founder, President and Chief Scientific Officer of 3-Dimensional Pharmaceuticals, Inc. (3DP), a publicly traded biotechnology company founded in 1993, and acquired by Johnson & Johnson in 2003. Dr. Salemme received the Ernst & Young Entrepreneur of the Year Award for Greater Philadelphia in 1998 for his role in building 3DP.

**Dr. Mark Ostro, Adviser:** Mark has considerable experience as a researcher, entrepreneur, company executive, Wall Street analyst and financial advisor. He founded the Liposome Company and assisted John Kulp with the commercialization of an earlier version of CFBD. Mark is currently Managing Partner, Devon Park Bioventures.

**Dr. Timothy Block, Adviser:** Tim is the Co-Founder and volunteer President of the Hepatitis B Foundation and its research affiliate the Institute for Hepatitis and Virus Research. Dr. Block is a Professor of Microbiology and Immunology, Drexel University College of Medicine, and Director of the Drexel Institute for Biotechnology and Virology Research. Dr. Block received his Ph.D. from SUNY and completed his post-doctoral training at Princeton University. He later studied at the University of Oxford, Sabbatical Fellow.

**Russ Craig, Adviser:** Russ has over 25 years of strategic consulting, line management and entrepreneurial experience. Russ started his consulting career at McKinsey and Co, where he dealt with high technology and industry clients. His experience includes Vice President and Director of the Electronics Practice at Arthur D. Little and Partner in Strategic Services at Accenture. Corporate Development Consulting.

**Andrew Powell, JD, Adviser:** Andrew is currently Senior Vice President and General Counsel for ImClone systems. Prior to joining ImClone, Andrew had over 20 years of legal experience, including 19 years in the healthcare industry. At CollaGenex Pharmaceuticals Andrew served as Vice President and General Counsel and at Baxter International, he held various leadership positions in the company's bioscience, international and European businesses. He graduated from the University of North Carolina at Chapel Hill and Stanford Law School.